Format

Send to

Choose Destination
Ann Intern Med. 2006 Jan 17;144(2):101-6.

Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis.

Author information

1
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. e.f.h.vanbommel@asz.nl

Abstract

BACKGROUND:

Anecdotal case reports suggest tamoxifen as a possible treatment for retroperitoneal fibrosis, but a systematic assessment of its effect is not available.

OBJECTIVE:

To describe the course and outcomes of patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen.

DESIGN:

Prospective, consecutive series.

SETTING:

Single tertiary care referral center.

PATIENTS:

19 patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen from April 1998 through April 2005.

INTERVENTION:

Tamoxifen, 20 mg orally twice daily.

MEASUREMENTS:

Clinical improvement, laboratory variables, and follow-up computed tomography (CT) and gallium scan findings.

RESULTS:

Fifteen patients reported substantial resolution of symptoms after a median treatment duration of 2.5 weeks. Erythrocyte sedimentation rate and C-reactive protein also improved. Gallium scanning at follow-up showed incomplete disappearance of pathologic gallium-67 activity. Repeated CT scanning showed slow but steady mass regression in 14 of 15 clinical responders. Five patients failed treatment, including 1 patient who improved clinically. Disease recurred in 1 patient who responded to reintroduction of tamoxifen. One patient developed reversible hepatitis.

LIMITATIONS:

This small observational study did not have a control group.

CONCLUSION:

Tamoxifen may be a viable therapeutic option in the treatment of retroperitoneal fibrosis.

Comment in

PMID:
16418409
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center